Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Inclusion Criteria

• •PDAC FAMILY HISTORY OR PDAC RELATED GENETIC MUTATIONS:
• •* Age: 50 or older, plus at least one of the following:
• •* Mutation unknown or absent:
• •* 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject;
• •* OR 2+ affected first degree relatives \[(FDR), defined as blood related parents, siblings, or children\]
• •* Known pathogenic/likely pathogenic (P/LP) mutation in at least one of the following:
• •* CDKN2A/p16, Peutz-Jeghers syndrome (PJS) serine/threonine kinase 11 (STK11), Hereditary pancreatitis with confirmed protease serine 1 (PRSS1)
• •* OR 1+ or second degree relative (SDR) with PDAC and a known P/LP mutation in one or more of:
• •* ATM, BRCA1, BRCA2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53
• •HIGH-RISK OR WORRISOME PANCREATIC CYSTS:
• •* 18 years of age or greater and meeting Fukuoka worrisome (FW) or Fukuoka high-risk (FHR) criteria
• •* High risk stigmata:
• •* Obstructive Jaundice in a patient with cystic lesion of the head of the pancreas
• •* Enhancing mural nodule ≥ 5 mm
• •* Main pancreatic duct ≥ 10 mm
• •* Worrisome features:
• •* Presence of pancreatic duct stricture, defined as focal pancreatic duct narrowing with upstream duct =\> 6 mm
• •* Cyst ≥ 3 cm
• •* Enhancing mural nodule \< 5 mm
• •* Thickened/Enhancing cyst wall
• •* Main duct size 5-9 mm
• •* Pancreatitis
• •* Lymphadenopathy
• •* Increased CA 19-9
• •* Cyst growth rate ≥ 5 mm /2 years